Purple Biotech Ltd ADR (PPBT)
2.46 x 1 2.59 x 2
Post-market by (Cboe BZX)
2.65 -0.05 (-1.85%) 04/28/25 [NASDAQ]
2.46 x 1 2.59 x 2
Post-market 2.48 -0.17 (-6.42%) 18:04 ET
for Mon, Apr 28th, 2025
Try Excel 
Watch
-
Add or delete the symbol from one or more Watchlists.
-
Create New Watchlist
This name already in use.
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,279 | -19,977 | -21,760 | -17,826 | -28,701 |
| Depreciation Amortization | 186 | 197 | 201 | 231 | 235 |
| Accounts receivable | N/A | N/A | N/A | -316 | -492 |
| Accounts payable and accrued liabilities | -2,076 | 1,334 | 799 | 399 | -2,355 |
| Other Working Capital | -4,332 | 274 | 3,255 | 744 | -3,438 |
| Other Operating Activity | -866 | -1,753 | 770 | 1,891 | 20,954 |
| Operating Cash Flow | $-14,367 | $-19,925 | $-16,735 | $-14,877 | $-13,797 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 2 | 15,803 | 19,658 | 10,248 | -49,618 |
| PPE Investments | N/A | -3 | -26 | -115 | -156 |
| Net Acquisitions | N/A | -3,549 | N/A | N/A | 69 |
| Purchase Of Investment | N/A | N/A | 160 | 2,914 | N/A |
| Sale Of Investment | 187 | 875 | N/A | N/A | N/A |
| Purchase Sale Intangibles | N/A | N/A | -202 | N/A | N/A |
| Other Investing Activity | 320 | 755 | 122 | 359 | 110 |
| Investing Cash Flow | $509 | $13,881 | $19,914 | $13,406 | $-49,595 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 5,809 | 6,563 | 1,498 | 1,764 | 74,046 |
| Other Financing Activity | 965 | -1,114 | -384 | -252 | -5,558 |
| Financing Cash Flow | $6,774 | $5,449 | $1,114 | $1,512 | $68,488 |
| Exchange Rate Effect | -4 | 54 | -153 | -24 | 61 |
| Beginning Cash Position | 14,489 | 15,030 | 10,890 | 11,247 | 4,385 |
| End Cash Position | 7,401 | 14,489 | 15,030 | 10,890 | 11,247 |
| Net Cash Flow | $-7,088 | $-541 | $4,140 | $-357 | $6,862 |
| Free Cash Flow | |||||
| Operating Cash Flow | -14,367 | -19,925 | -16,735 | -14,877 | -13,797 |
| Capital Expenditure | N/A | -3 | -26 | -115 | -156 |
| Free Cash Flow | -14,367 | -19,928 | -16,761 | -14,992 | -13,953 |